Rituximab



General description

Rituximab is a monoclonal antibody used in treatment protocols for lymphomas and leukaemia, as well as various autoimmune inflammatory diseases.

INN	Rituximab
ATC codes	L01FA01
Medicine type	Biological agent
EML status history	First added in 2015 (TRS 994) for Diffuse large B-cell lymphoma, not otherwise specified Changed in 2015 (TRS 994) for Chronic lymphocytic leukaemia or small lymphocytic lymphoma Changed in 2015 (TRS 994) for Follicular lymphoma Changed in 2023 (TRS 1049) for Multiple sclerosis Changed in 2023 (TRS 1049) for Burkitt lymphoma including Burkitt leukaemia
Wikipedia	Rituximab
DrugBank	Rituximab

Recommendations

Section Targeted therapies

- Parenteral > General injections > IV: 100 mg per 10 mL in 10 mL vial; 500 mg per 50 mL in 50 mL vial

Indications

Diffuse large B-cell lymphoma, not otherwise specified

Chronic lymphocytic leukaemia or small lymphocytic lymphoma

Follicular lymphoma

Burkitt lymphoma including Burkitt leukaemia

Section Medicines for multiple sclerosis

- Parenteral > General injections > IV: 500 mg per 50 mL in 50 mL vial

Indications

Multiple sclerosis